Sandbox Rim: Difference between revisions

	High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
Sandbox Rim On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox Rim All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox Rim
CDC on Sandbox Rim
Sandbox Rim in the news
Blogs on Sandbox Rim
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for Sandbox Rim

VisualWikitext

Revision as of 15:24, 18 August 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Objective

Sponsor

Timeline

Timeline
Start Date
End Date
Status

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00136981.

Study Description

Study Description
Study Type
Study Phase
Study Design
Allocation
Endpoint
Interventional Model
Masking
Study Details
Primary Purpose
Condition
Intervention
Study Arms
Population Size

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00136981.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcomes

Primary Outcomes

Publications

Results

Conclusion

Pending

References

@@ Line 1: / Line 1: @@
-==Instruments==
+__NOTOC__
-The heart has four chambers.  The [[atrium]] is bla bla.<ref name="pmid11848459">{{cite journal| author=Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S| title=Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. | journal=Thromb Haemost | year= 2002 | volume= 87 | issue= 1 | pages= 7-12 | pmid=11848459 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11848459  }} </ref>
+{{High density lipoprotein}}
-==During the Procedure==
+{{CMG}}; {{AE}} {{Rim}}
-[[File:Keratosis solar24.jpg|200px]]
+==Official Title==
-==Complications==
-===Complication 1===
-Clues for this complication are:
-* A
-* B
-* C
-* D
-===Complication 2===
+==Objective==
-===Complication 3===
+==Sponsor==
-bvjsdlkhnedvuvjhnvij.
-aaaaaaaaaaaaaa
-==Refernces==
+==Timeline==
+{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%"
+|-
+| Colspan="2" style="background:Gainsboro" align="center"|'''Timeline'''
+|-
+| Style="width:30%"| '''Start Date'''||Style="width:70%"|
+|-
+| '''End Date'''||
+|-
+| '''Status'''||
+|-
+|}
+<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00136981.</span>
+==Study Description==
+{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%"
+|-
+| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description'''
+|-
+| Style="width:30%"|'''Study Type'''|| Style="width:70%"|
+|-
+| '''Study Phase''' ||
+|-
+| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design'''
+|-
+| '''Allocation'''||
+|-
+| '''Endpoint'''||
+|-
+| '''Interventional Model'''||
+|-
+| '''Masking'''||
+|-
+| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details'''
+|-
+| '''Primary Purpose'''||
+|-
+| '''Condition'''||
+|-
+| '''Intervention'''||
+|-
+| '''Study Arms'''||
+|-
+| '''Population Size'''||
+|-
+|}
+<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00136981.</span>
+==Eligibility Criteria==
+===Inclusion Criteria===
+===Exclusion Criteria===
+==Outcomes==
+===Primary Outcomes===
+==Publications==
+===Results===
+===Conclusion===
+Pending
+==References==
 {{Reflist|2}}
+{{Lipopedia}}
+[[Category:Lipopedia]]
+[[Category:HDL]]
+[[Category:Clinical trials]]
+[[Category:HDLpedia]]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL